Individual Versus Group Exposure With Response Prevention (ERP) for the Treatment of Obsessive Compulsive Disorder (OCD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03926546 |
Recruitment Status :
Withdrawn
(The former principal investigator left the institution.)
First Posted : April 24, 2019
Last Update Posted : May 27, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
OCD | Behavioral: ERP for Individuals | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Individual Versus Group Exposure and Response Prevention Therapy for the Treatment of Obsessive-Compulsive Disorder |
Estimated Study Start Date : | May 2020 |
Estimated Primary Completion Date : | December 2020 |
Estimated Study Completion Date : | February 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Individual ERP
Individual Exposure and Response Prevention for OCD
|
Behavioral: ERP for Individuals
Comparing Group vs. Individual ERP for OCD
Other Name: ERP for Groups |
Experimental: Group ERP
Group Exposure and Response Prevention for OCD
|
Behavioral: ERP for Individuals
Comparing Group vs. Individual ERP for OCD
Other Name: ERP for Groups |
- Yale-Brown Obsessive-Compulsive Scale [ Time Frame: Post-treatment, 6 weeks after baseline ]Participant OCD severity is measured with Yale-Brown Obsessive-Compulsive Scale over the course of their time in the study. Severity is measured at baseline (week 1), mid (week 3), and post (week 6) participation in ERP over the course of 6 weeks. Severity on the scale is measured based on a score range of 0-40. Participants with scores of 0-13 are considered to have mild symptoms. Scores of 14-25 are considered moderate. 26-34 are considered to be moderate-severe. 35-40 are considered to be very severe.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participants must be adults 18 years or older.
- Participants must have the capacity and ability to give informed consent.
- Participants have been given an assessment and received a diagnosis of OCD.
- Participants must speak English.
- Participants must be able to physically attend treatment.
Exclusion Criteria:
- Prisoners or any other high-risk population group.
- experiencing active psychosis
- experiencing active substance abuse disorder
- experiencing active suicidality

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03926546
United States, Texas | |
Baylor College of Medicine Jamail Building | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Elizabeth McIngvale, Ph.D. | Baylor College of Medicine |
Responsible Party: | Eric Alan Storch, Professor, Psychiatry Research, Baylor College of Medicine |
ClinicalTrials.gov Identifier: | NCT03926546 |
Other Study ID Numbers: |
H-44611 |
First Posted: | April 24, 2019 Key Record Dates |
Last Update Posted: | May 27, 2020 |
Last Verified: | May 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Compulsive Personality Disorder Obsessive-Compulsive Disorder Personality Disorders Mental Disorders Anxiety Disorders |